Additionally, to investigate the molecular mechanisms underlying the anticancer effects of SMYD2 inhibitors, miRNA-expression profiles in ccRCC cells were analyzed after their treatment with AZ505. The gene discussed is SMYD2; the disease is nonpapillary renal cell carcinoma.